Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $486.67 Average Target Price from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned an average recommendation of “Hold” from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $486.6667.

MEDP has been the topic of several research analyst reports. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a report on Friday, March 6th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target for the company in a research report on Tuesday, February 10th. Finally, Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th.

Medpace Price Performance

Shares of MEDP opened at $460.92 on Friday. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The stock has a market cap of $13.08 billion, a PE ratio of 30.13, a price-to-earnings-growth ratio of 2.18 and a beta of 1.44. The firm has a fifty day moving average price of $511.94 and a 200 day moving average price of $538.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the company posted $3.67 earnings per share. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts expect that Medpace will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC grew its stake in shares of Medpace by 7.0% in the 4th quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock valued at $1,029,000 after purchasing an additional 120 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Medpace during the fourth quarter worth approximately $2,164,000. Worthington Financial Partners LLC purchased a new stake in shares of Medpace during the fourth quarter worth approximately $1,082,000. Bayban acquired a new stake in shares of Medpace during the fourth quarter worth $44,000. Finally, Pacer Advisors Inc. lifted its holdings in shares of Medpace by 38.1% during the fourth quarter. Pacer Advisors Inc. now owns 153,652 shares of the company’s stock worth $86,299,000 after purchasing an additional 42,362 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.